注冊以創建關於儀器的通知
你所追隨的作者的經濟活動和內容
免費註冊 已有帳戶? 登入
I-Mab是一家總部位於中國的公司,主要從事創新全球生物技術的開發。該公司的主要業務包括從事創新記錄、開發創新候選藥物以及進行資產和商業化的臨床驗證。該公司在研產品由十項臨床階段資產和十項臨床前資產組成,其中七項資產已進入二期或三期臨床試驗階段。其管道預計將產生三個近期NDA申請和/或產品發布,包括用於多發性骨髓瘤(MM)的felzartamab、用於兒科生長激素缺乏症(PGHD)的eftansomatropin alfa,以及潛在的用於骨髓增生異常綜合徵(MDS)的lemzoparlimab,以及後來用於急性髓性白血病(AML)和非霍奇金淋巴瘤(NHL)的藥物。
名稱 | 年齡 | 成立於 | 主旨 |
---|---|---|---|
Xi Liu | - | 2021 | Independent Director |
Patricia LoRusso | - | 2019 | Member of Scientific Advisory Board |
Pamela M. Klein | 63 | 2020 | Interim Chairperson |
Howard L. Weiner | 77 | 2019 | Member of Scientific Advisory Board |
Timothy A. Yap | 49 | 2019 | Member of Scientific Advisory Board |
Roy Steven Herbst | 61 | 2019 | Member of Scientific Advisory Board |
Chia-Hung Yang | 61 | 2020 | Independent Director |
Jun Ma | - | 2020 | Member of Scientific Advisory Board |
Wei Fu | 42 | 2018 | Director |
Chun Kwok Au | 51 | 2020 | Independent Director |
Rong Shao | 62 | 2021 | Independent Director |
Yi-Long Wu | - | 2019 | Member of Scientific Advisory Board |
Chen Dong | - | 2020 | Member of Scientific Advisory Board |
Eric K. Rowinsky | 67 | 2019 | Member of Scientific Advisory Board |
Ruyi He | 62 | 2021 | Independent Director |
Raj Kannan | 60 | 2023 | CEO & Director |
Shuai Chen | 50 | 2023 | Director |
你確定要封鎖 %USER_NAME%?
此舉將會令你與 %USER_NAME% 之間無法看見對方的Investing.com貼文。
%USER_NAME% 已成功加入你的封鎖清單
你剛解除此人的封鎖,必須等候 48 小時後才可再次封鎖。
我覺得這個評論是:
謝謝!
您的報告已被發送到我們的版主審核